A detailed history of Deutsche Bank Ag\ transactions in Altimmune, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 55,792 shares of ALT stock, worth $449,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,792
Previous 40,435 37.98%
Holding current value
$449,125
Previous $268,000 27.61%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.5 - $8.1 $84,463 - $124,391
15,357 Added 37.98%
55,792 $342,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $18,634 - $32,255
-3,153 Reduced 7.23%
40,435 $268,000
Q1 2024

May 15, 2024

SELL
$8.22 - $13.81 $142,189 - $238,885
-17,298 Reduced 28.41%
43,588 $443,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $65,180 - $353,921
30,458 Added 100.1%
60,886 $684,000
Q3 2023

Nov 09, 2023

BUY
$2.4 - $3.45 $73,027 - $104,976
30,428 New
30,428 $79,000
Q2 2022

Aug 11, 2022

SELL
$3.94 - $11.77 $85,285 - $254,773
-21,646 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$5.9 - $9.45 $14,384 - $23,039
-2,438 Reduced 10.12%
21,646 $132,000
Q4 2021

Feb 11, 2022

BUY
$8.69 - $12.48 $11,140 - $15,999
1,282 Added 5.62%
24,084 $221,000
Q3 2021

Nov 04, 2021

BUY
$8.43 - $16.81 $29,572 - $58,969
3,508 Added 18.18%
22,802 $258,000
Q2 2021

Aug 11, 2021

BUY
$9.85 - $16.46 $190,045 - $317,579
19,294 New
19,294 $190,000
Q3 2019

Nov 14, 2019

SELL
$1.95 - $2.66 $195 - $266
-100 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$2.54 - $4.54 $251 - $449
99 Added 9900.0%
100 $0
Q3 2018

Dec 21, 2021

SELL
$4.27 - $26.23 $4 - $26
-1 Reduced 50.0%
1 $0
Q3 2018

Nov 14, 2018

BUY
$4.27 - $26.23 $8 - $52
2 New
2 $0

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.